itle: Sugar Modified Oligonucleotides
aventors: Phillip Dan Cook and Andrew M

waski

Sheet 1 of 9






FIG.I

Ļ., 쁖 ļa:

T Sugar Modified Oligonucleotides
Inventors: Phillip Dan Cook and Andrew M. Ka

Sheet 2 of 9

2/9




FIG.2

Tit Sugar Modified Oligonucleotides

ors: Phillip Dan Cook and Andrew M. Kat

Sheet 3 of 9

Ų,

lai:

3/9
EFFECT OF 2'-O-METHYL GAPPED OLIGOS

4.0 kb




FIG.3

itle: Sugar Modified Oligonucleotides


nventors: Phillip Dan Cook and Andrew M waski

Sheet 4 of 9

ļai:

4/9

4.0 kb 8.5 kb



OLIGONUCLEOTIDE TREATMENT (HRS)

FIG.4

Sugar Modified Oligonucleotides

nventors: Phillip Dan Cook and Andrew M. K.

Sheet 5 of 9


Ļį,

ļ.

Ħ.

5/9

4.0 kb




OLIGONUCLEOTIDE TREATMENT (HRS)

FIG.5

DOCKET NO.: ISIS-4943

tle: Sugar Modified Oligonucleotides
Andrew M. Waski
Sheet 6 of 9



Sugar Modified Oligonucleotides
In entors: Phillip Dan Cook and Andrew M. Ka.

Sheet 7 of 9

7/9

ISIS 3082 TISSUE DISTRIBUTION IN BALB/c MICE AS PERCENT OF DOSE AT I, 3, 8 AND 24 HOURS AFTER INTRAVENOUS INJECTION




FIG.7

T Sugar Modified Oligonucleotides

Inventors: Phillip Dan Cook and Andrew M. Karak

Sheet 8 of 9

8/9

ISIS 9045 (2' O-PROPYL PHOSPHOROTHIATE ANALOG OF ISIS 3082) TISSUE DISTRIBUTION IN BALB/c MICE AS PERCENT OF DOSE AT I, 3, 8 AND 24 HOURS AFTER INTRAVENOUS INJECTION




FIG.8

DOUKET NO.: ISIS-4943
Sugar Modified Oligonucleotides
Inventors: Phillip Dan Cook and Andrew M. K
Sheet 9 of 9

9/9
TISSUE DISTRIBUTION OF ISIS 9046 (2' O-PROPYL GAPMER) IN BALB/c MICE AT I, 3, 8 AND 24 HOURS AFTER INTRAVENOUS INJECTION




FIG.9